Tergus Pharma partners with Great Point Partners to build a new commercial manufacturing facility.
A 100,000 square feet new expansion will provide comprehensive services from development through manufacturing and will become a Contract Development and Manufacturing Organisation, or CDMO.
The new US$ 35million facility will be provide an employment for 200 people over the next five years after building a new headquarters and a commercial manufacturing centre.
Tergus announced a partnership with the Great Point Partners (GPP), a healthcare invest firm.
New construction provides Topical Formulation development, In Vitro Release Testing (IVRT), in vitro Permeating Testing (IVPT), Analytical services, Skin Biology, and Clinical Trial Materials (CTM) manufacturing services for branded and generic dermatology products.
GPP's investment will allow Tergus Pharma to build a state-of-art commercial manufacturing building in the Raleigh-Durham. This new Construction will increase the current capacity by over 400 per cent.
The new facility is expected to be operational in early 2020.
|US$ 35 million
|Great Point Partners (GPP)
|Scheduled to be open in early 2020